Abstract

Colorectal cancer (CRC) is the third most common cancer, and is the third most common cause of death due to cancer in both women and men. Approximately 20 percent of patients with newly diagnosed colon cancer have distant metastatic disease at the time of diagnosis. Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and it is commonly used to treat metastatic colorectal cancer (mCRC). Combinations of panitumumab plus an irinotecan or oxaliplatin-based regimen are reasonable both first-line and second-line options for mCRC with RAS wild type tumors. However, it has been associated with various side effects such as papulopustular acneiform rash, hypomagnesemia, and diarrhea. No previous reports on patients who developed tongue pain without stomatitis while treatment with panitumumab exists in the literature. Here we report two cases that developed tongue pain while on panitumumab for mCRC.

Key words: Panitumumab; Tongue Pain; Metastatic Colorectal Cancer.